Regeneron (REGN) Highlights Positive Topline Results in Phase 3 Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Regeneron (REGN) Tops Q2 EPS by 61c, Revenues Beat
August 6, 2019 6:43 AM EDTRegeneron (NASDAQ: REGN) reported Q2 EPS of $6.02, $0.61 better than the analyst estimate of $5.41. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.8 billion.
Second quarter 2019 revenues increased 20% to $1.93 billion versus second quarter 2018EYLEA® U.S. net sales increased 17% to $1.16 billion versus second quarter 2018Dupixent® global net sales, which are recorded by the Company's collaborator Sanofi, increased 166% to $557... MoreRegeneron (REGN) Reports Dupixent Granted European Commission Approval for Adolescents with Moderate-to-Severe Atopic Sermatitis
August 6, 2019 5:57 AM EDTRenegeron (NASDAQ: REGN) announced the European Commission (EC) today extended the marketing authorization for Dupixent® (dupilumab) in the European Union (EU) to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Dupixent is now the first biologic medicine approved in the EU to treat these patients.
Moderate-to-severe atopic dermatitis can affect many aspects of an adolescents life, including their physical and emotional well-being, said Christine Janus, Chief Executive Officer of the International Alliance of Dermatology Patient... More
